REVA Medical Inc.'s 12-Month Data From RESTORE Trial and ReZolve2 Program Update
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
SAN DIEGO, May 21, 2013 (GLOBE NEWSWIRE) -- At the Paris Course on Revascularization ("EuroPCR") being held this week in Paris, France, REVA Medical, Inc. (ASX:RVA) ("REVA" or the "Company") released 12-month data on a subset of patients enrolled in the RESTORE clinical trial. The RESTORE trial is evaluating the safety and performance of the first-generation ReZolve® sirolimus-eluting bioresorbable coronary scaffold, which was implanted in 22 patients between December 2011 and July 2012.
Help employers find you! Check out all the jobs and post your resume.
SAN DIEGO, May 21, 2013 (GLOBE NEWSWIRE) -- At the Paris Course on Revascularization ("EuroPCR") being held this week in Paris, France, REVA Medical, Inc. (ASX:RVA) ("REVA" or the "Company") released 12-month data on a subset of patients enrolled in the RESTORE clinical trial. The RESTORE trial is evaluating the safety and performance of the first-generation ReZolve® sirolimus-eluting bioresorbable coronary scaffold, which was implanted in 22 patients between December 2011 and July 2012.
Help employers find you! Check out all the jobs and post your resume.